Critical IllnessSOFA2-GISNCT07586254
Adding a Gastrointestinal Subscore to SOFA2 for Mortality Risk Assessment in the ICU: The SOFA2-GIS Study
An observational study of Critical Illness and Multiple Organ Failure, run by Ozkul Yilmaz Colak at 1 site in Turkey (Türkiye).
Trial summary
The goal of this observational study is to learn whether adding a gastrointestinal (GI) component to a widely used organ failure score improves the prediction of death risk in critically ill adults treated in the intensive care unit (ICU). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Critical Illness, Multiple Organ Failure, Gastrointestinal Diseases
- How many people
- 800 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- Jul 2026to Mar 2027
- How long will I take part?
- 3 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients (≥18 years) consecutively admitted to participating tertiary intensive care units in Türkiye. The study population includes both medical and surgical ICU admissions, with a broad mix of admission diagnoses representative of contemporary critical care practice. Patients will be enrolled regardless of underlying disease, as long as they meet eligibility criteria within the first 24 hours of ICU admission.
Who may be able to join
- Adults aged 18 years or older
- Admission to a participating intensive care unit
- Expected ICU length of stay of at least 24 hours
- Availability of clinical and laboratory data required to calculate the SOFA2 score and the AGI grade within the first 24 hours of ICU admission
- Written informed consent obtained from the patient or, when not feasible due to the patient's clinical condition, from a legally authorized representative
Who cannot join
- Age younger than 18 years
- Pregnancy
- ICU length of stay shorter than 24 hours (including patients who die or are discharged within the first 24 hours)
- ICU readmission during the same hospital stay (only the index admission will be included)
- Postoperative admission for routine monitoring without organ dysfunction (planned short-term observation following elective surgery)
- Admission solely for end-of-life care or with treatment limitations (do-not-resuscitate or withdrawal of life-sustaining therapy decisions) made within the first 24 hours of admission
Show all 10Show fewer
- Patients with primary gastrointestinal pathology as the reason for ICU admission that would confound AGI grading (e.g., gastrointestinal surgery within the preceding 7 days, acute mesenteric ischemia as the primary diagnosis)
- Patients with anatomical or functional conditions precluding standard AGI assessment (e.g., short bowel syndrome, permanent gastrostomy/jejunostomy with chronic feeding intolerance, chronic intestinal pseudo-obstruction)
- Refusal of consent by the patient or legal representative
- Participation in an interventional clinical trial that may affect outcome measures
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Melda Isevi, MD contact
Turkey (Türkiye)1 site
Ondokuz Mayis University
Samsun, Atakum, 55002
Ozkul Yilmaz Colak, MD, 905063349266, ozkulyilmaz.colak@omu.edu.tr
About this study
Official title: Development and Validation of the SOFA2-GIS Score: Adding a Gastrointestinal Subscore to SOFA2 for Mortality Risk Assessment in Critically Ill Patients - A Multicenter Prospective Observational Cohort Study
The goal of this observational study is to learn whether adding a gastrointestinal (GI) component to a widely used organ failure score improves the prediction of death risk in critically ill adults treated in the intensive care unit (ICU).
The Sequential Organ Failure Assessment 2 (SOFA2) score is used in ICUs to measure how severely a patient's organs are failing. The current version evaluates six organ systems but does not include the gastrointestinal system, even though gut dysfunction is common and serious in critically ill patients. Researchers in this study will add a GI subscore based on the European Society of Intensive Care Medicine (ESICM) Acute Gastrointestinal Injury (AGI) classification and create a new combined score called SOFA2-GIS.
Read more
The main questions this study aims to answer are:
Does adding a gastrointestinal subscore to the SOFA2 score improve the prediction of 28-day mortality in ICU patients? Does the new SOFA2-GIS score perform better than the standard SOFA2 score in identifying patients at higher risk of dying in the ICU or in the hospital?
Researchers will compare the standard SOFA2 score with the new SOFA2-GIS score in the same patients to see which one better predicts patient outcomes.
Participants will:
Receive their usual ICU care without any change, additional treatment, or extra tests Be evaluated using routinely collected clinical and laboratory information during the first 24 hours of ICU admission Be followed during their hospital stay to record outcomes such as length of stay, need for mechanical ventilation, need for dialysis, and survival
This is a multicenter, prospective, observational cohort study conducted in tertiary ICUs in Türkiye. No additional procedures, tests, or interventions will be performed for the purpose of this study.
Read the detailed description
Background and Rationale The Sequential Organ Failure Assessment (SOFA) score, originally introduced in 1996, has been widely used to describe and monitor organ dysfunction in critically ill patients across six organ systems: respiratory, cardiovascular, hepatic, renal, neurological, and coagulation. A revised version, SOFA2, was developed in 2024 by an international consortium under the European Society of Intensive Care Medicine (ESICM) to better reflect contemporary intensive care practice and to incorporate evidence-based threshold revisions derived from large modern ICU databases.
Despite this update, SOFA2 still does not include the gastrointestinal (GI) system. Acute gastrointestinal dysfunction is highly prevalent in critically ill patients and has been independently associated with increased mortality, prolonged ICU stay, and higher rates of nosocomial infection. The Acute Gastrointestinal Injury (AGI) classification, proposed by the ESICM Working Group on Abdominal Problems in 2012, provides a structured framework to grade GI dysfunction from Grade I (increased risk of GI dysfunction) to Grade IV (life-threatening GI failure). Despite its conceptual robustness, the AGI classification has not been formally integrated into a unified organ dysfunction score.
This study aims to address this gap by developing and prospectively evaluating SOFA2-GIS - a composite score combining the SOFA2 score with a gastrointestinal subscore derived from the AGI classification - and comparing its prognostic performance against the standard SOFA2 score in adult ICU patients. The study will be reported in accordance with the TRIPOD+AI 2024 reporting standards for prediction model studies.
Study Design and Procedures
This is a multicenter, prospective, observational cohort study conducted in tertiary adult intensive care units. Eligible patients will be evaluated at two predefined time points:
T24 (primary time point): Within the first 24 hours of ICU admission, the worst values of clinical and laboratory parameters will be used to calculate the SOFA2 score and the AGI grade. The two components will then be combined to derive the SOFA2-GIS score.
T72 (secondary time point): At the 72nd hour (±6 hours) of ICU admission, both scores will be recalculated using cross-sectional measurements, allowing the calculation of Δ-SOFA2 and Δ-SOFA2-GIS (T72 - T24).
AGI grading will follow the original ESICM 2012 criteria, based on clinical symptoms, feeding intolerance, intra-abdominal pressure, gastric residual volume, diarrhea, and gastrointestinal bleeding. To ensure consistency across centers, all participating investigators will undergo standardized training on AGI assessment. Inter-rater agreement will be evaluated through a pilot phase using shared cases prior to the main enrollment period.
No additional interventions, laboratory tests, imaging studies, or sampling procedures will be performed for the purpose of this study. All data will be derived from information collected during routine clinical care.
Data Collection
Data will be collected at the participating sites using a standardized case report form. In addition to the SOFA2 and AGI components, the following variables will be recorded:
Demographic characteristics, comorbidities (Charlson Comorbidity Index), admission category, and admission diagnosis Vital signs, laboratory parameters, mechanical ventilation parameters (including plateau and peak airway pressures), vasopressor use, and renal replacement therapy requirement Sepsis status according to the Sepsis-3 definition Lactate values at baseline, 24th hour, and 72nd hour, and the 24-hour lactate clearance 24-hour cumulative fluid balance Daily caloric intake (DCI) averaged over the first 72 hours (kcal/kg/day) Feeding intolerance, gastrointestinal bleeding, intra-abdominal hypertension, abdominal compartment syndrome, and decompressive laparotomy Acute kidney injury staged according to KDIGO criteria Clinical outcomes: ICU and hospital length of stay, ventilator-free days, vasopressor-free days, renal replacement therapy-free days, 28-day mortality, and 90-day mortality Each participating site will record anonymized patient data into a shared spreadsheet template. The data will then be transferred to and consolidated at the coordinating center, which will not have access to patient identifiers.
Statistical Approach The discriminative performance of SOFA2 and SOFA2-GIS for predicting 28-day mortality (primary outcome) will be compared using the area under the receiver operating characteristic curve (AUC-ROC), with statistical comparison performed via the DeLong test. Calibration will be assessed using the Hosmer-Lemeshow test and calibration plots. Reclassification performance will be evaluated using the net reclassification improvement (NRI) and integrated discrimination improvement (IDI) indices. Multicollinearity between score components will be assessed using the variance inflation factor (VIF).
Secondary analyses will include: comparison of Δ-SOFA2 and Δ-SOFA2-GIS (T72 - T24) for outcome prediction, subgroup analyses by admission category (medical, surgical, septic) and AGI severity grade, evaluation of the interaction between lactate clearance and AGI grade, and the development of a clinically applicable nomogram based on the best-performing model.
Study Conduct The study will be conducted in accordance with the principles of the Declaration of Helsinki. The coordinating center is the Internal Medicine Intensive Care Unit of Ondokuz Mayıs University. Participating centers will join through an open call disseminated via Turkish intensive care societies, following completion of their respective institutional approvals. Each center will obtain its own local ethics committee approval prior to enrolling patients. Reporting will follow the TRIPOD+AI 2024 guideline.
- Keywords
- sofa2, sofa-2, Sequential Organ Failure Assessment, SOFA2-GIS, Organ dysfunction score, Prognostic score, ICU mortality
- Medical subject headings
- Critical Illness, Multiple Organ Failure, Gastrointestinal Diseases
What is being measured
The primary outcome is the main question the study is designed to answer.
Comparison of discriminative performance between SOFA2 and SOFA2-GIS scores for 28-day all-cause mortality
The primary outcome is the difference in the area under the receiver operating characteristic curve (ΔAUC) between the SOFA2-GIS score and the SOFA2 score for predicting 28-day all-cause mortality.
Both scores are calculated within the first 24 hours of ICU admission using the worst recorded values of each component. The Sequential Organ Failure Assessment 2 (SOFA2) score evaluates six organ systems (respiratory, cardiovascular, hepatic, renal, neurological, and coagulation), each scored from 0 to 4, with a total range of 0 to 24; higher scores indicate worse organ dysfunction. The SOFA2-GIS score combines SOFA2 with a gastrointestinal subscore (Grade 0-IV, scored 0-4) derived from the ESICM 2012 Acute Gastrointestinal Injury classification, with a total range of 0 to 28; higher scores indicate worse organ dysfunction.
The area under the receiver operating characteristic curve (AUC-ROC) ranges from 0.5 (no discrimination) to 1.0 (perfect discrimination); higher values indicate better
Measured: 28 days from ICU admission
Secondary outcomes (5)
Difference in discriminative performance (ΔAUC) between SOFA2-GIS and SOFA2 for prediction of 90-day all-cause mortality
The difference in the area under the receiver operating characteristic curve (ΔAUC) between SOFA2-GIS and SOFA2 scores (calculated within the first 24 hours of ICU admission) will be evaluated for predicting 90-day all-cause mortality. ΔAUC = AUC(SOFA2-GIS) - AUC(SOFA2). AUC-ROC ranges from 0.5 to 1.0; ΔAUC ranges from -0.5 to +0.5, with positive values indicating better performance of SOFA2-GIS. Statistical comparison via the DeLong test.
Measured: 90 days from ICU admission
Difference in discriminative performance (ΔAUC) between SOFA2-GIS and SOFA2 for prediction of ICU mortality
The difference in AUC-ROC between SOFA2-GIS and SOFA2 scores will be evaluated for predicting all-cause ICU mortality. ΔAUC = AUC(SOFA2-GIS) - AUC(SOFA2), ranges from -0.5 to +0.5; positive values indicate better performance of SOFA2-GIS. Statistical comparison via the DeLong test.
Measured: Through ICU discharge, up to 60 days from ICU admission
Difference in discriminative performance (ΔAUC) between Δ-SOFA2-GIS and Δ-SOFA2 for prediction of 28-day all-cause mortality
Δ-SOFA2 and Δ-SOFA2-GIS will be calculated as the change in scores between the 72nd hour and 24th hour of ICU admission (T72 - T24). Δ-SOFA2 ranges from -24 to +24, and Δ-SOFA2-GIS ranges from -28 to +28; positive values indicate clinical deterioration, negative values indicate improvement. The difference in AUC-ROC between Δ-SOFA2-GIS and Δ-SOFA2 for predicting 28-day all-cause mortality will be calculated as ΔAUC = AUC(Δ-SOFA2-GIS) - AUC(Δ-SOFA2), with statistical comparison via the DeLong test.
Measured: From ICU admission to 28 days
Net Reclassification Improvement (NRI) of SOFA2-GIS over SOFA2 for 28-day all-cause mortality
Net Reclassification Improvement (NRI) quantifies the proportion of patients reclassified into more accurate risk categories when SOFA2-GIS is used instead of SOFA2 for predicting 28-day all-cause mortality. NRI ranges from -2 to +2; positive values indicate that SOFA2-GIS improves risk classification compared with SOFA2.
Measured: 28 days from ICU admission
Intensive care unit length of stay
Time from ICU admission to ICU discharge alive, ICU death, or transfer to another ICU, measured in days. Patients still in ICU at day 60 will be right-censored at day 60. Association of SOFA2 and SOFA2-GIS scores with ICU length of stay will be assessed using time-to-event analysis (Cox proportional hazards regression, treating death as a competing risk).
Measured: Up to 60 days from ICU admission
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 May 2026
- Study startJul 2026 (estimated)
- Primary completionDec 2026 (estimated)
- Study completionMar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Critical IllnessStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 800 participants (estimated)
- Target duration
- 3 Months
Sponsor and investigators
- Lead sponsor
- Ozkul Yilmaz Colak
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Ozkul Yilmaz Colak, Ondokuz Mayıs University
- Investigators
- Ozkul Yilmaz Colak, MD, Study director, Ondokuz Mayıs University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07586254
- Sponsor's protocol ID
- ICU-SOFAGIS-2026-01
- Acronym
- SOFA2-GIS
- Status last verified
- May 2026
- First submitted
- 8 May 2026
- Last updated
- 26 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual participant data (IPD) collected during the SOFA2-GIS study, including all variables underlying the published findings, will be made available. The dataset will include patient demographics, comorbidities, admission diagnosis, SOFA2 and AGI score components, laboratory parameters, hemodynamic and ventilatory parameters, lactate values, daily caloric intake, fluid balance, complications, and clinical outcomes (28-day, ICU, hospital, and 90-day mortality, length of stay, ventilator-free days, vasopressor-free days, RRT-free days). All direct patient identifiers will be removed prior to data sharing.
Study at a glance
From the registry record, last updated by the sponsor on 26 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Development and Validation of the SOFA2-GIS Score: Adding a Gastrointestinal Subscore to SOFA2 for Mortality Risk Assessment in Critically Ill Patients - A Multicenter Prospective Observational Cohort Study
- ClinicalTrials.gov ID
- NCT07586254
- Acronym / sponsor ID
- SOFA2-GIS / ICU-SOFAGIS-2026-01
- Keywords
- sofa2, sofa-2, Sequential Organ Failure Assessment, SOFA2-GIS, Organ dysfunction score, Prognostic score, ICU mortality
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 800 participants (estimated)
- Lead sponsor
- Ozkul Yilmaz ColakUniversity, hospital or other
- Study start
- Jul 2026 (estimated)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Mar 2027 (estimated)
- First posted
- 14 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to learn whether adding a gastrointestinal (GI) component to a widely used organ failure score improves the prediction of death risk in critically ill adults treated in the intensive care unit (ICU).
The Sequential Organ Failure Assessment 2 (SOFA2) score is used in ICUs to measure how severely a patient's organs are failing. The current version evaluates six organ systems but does not include the gastrointestinal system, even though gut dysfunction is common and serious in critically ill patients. Researchers in this study will add a GI subscore based on the European Society of Intensive Care Medicine (ESICM) Acute Gastrointestinal Injury (AGI) classification and create a new combined score called SOFA2-GIS.
The main questions this study aims to answer are:
Does adding a gastrointestinal subscore to the SOFA2 score improve the prediction of 28-day mortality in ICU patients? Does the new SOFA2-GIS score perform better than the standard SOFA2 score in identifying patients at higher risk of dying in the ICU or in the hospital?
Researchers will compare the standard SOFA2 score with the new SOFA2-GIS score in the same patients to see which one better predicts patient outcomes.
Participants will:
Receive their usual ICU care without any change, additional treatment, or extra tests Be evaluated using routinely collected clinical and laboratory information during the first 24 hours of ICU admission Be followed during their hospital stay to record outcomes such as length of stay, need for mechanical ventilation, need for dialysis, and survival
This is a multicenter, prospective, observational cohort study conducted in tertiary ICUs in Türkiye. No additional procedures, tests, or interventions will be performed for the purpose of this study.
Detailed description
Background and Rationale The Sequential Organ Failure Assessment (SOFA) score, originally introduced in 1996, has been widely used to describe and monitor organ dysfunction in critically ill patients across six organ systems: respiratory, cardiovascular, hepatic, renal, neurological, and coagulation. A revised version, SOFA2, was developed in 2024 by an international consortium under the European Society of Intensive Care Medicine (ESICM) to better reflect contemporary intensive care practice and to incorporate evidence-based threshold revisions derived from large modern ICU databases.
Despite this update, SOFA2 still does not include the gastrointestinal (GI) system. Acute gastrointestinal dysfunction is highly prevalent in critically ill patients and has been independently associated with increased mortality, prolonged ICU stay, and higher rates of nosocomial infection. The Acute Gastrointestinal Injury (AGI) classification, proposed by the ESICM Working Group on Abdominal Problems in 2012, provides a structured framework to grade GI dysfunction from Grade I (increased risk of GI dysfunction) to Grade IV (life-threatening GI failure). Despite its conceptual robustness, the AGI classification has not been formally integrated into a unified organ dysfunction score.
This study aims to address this gap by developing and prospectively evaluating SOFA2-GIS - a composite score combining the SOFA2 score with a gastrointestinal subscore derived from the AGI classification - and comparing its prognostic performance against the standard SOFA2 score in adult ICU patients. The study will be reported in accordance with the TRIPOD+AI 2024 reporting standards for prediction model studies.
Study Design and Procedures
This is a multicenter, prospective, observational cohort study conducted in tertiary adult intensive care units. Eligible patients will be evaluated at two predefined time points:
T24 (primary time point): Within the first 24 hours of ICU admission, the worst values of clinical and laboratory parameters will be used to calculate the SOFA2 score and the AGI grade. The two components will then be combined to derive the SOFA2-GIS score.
T72 (secondary time point): At the 72nd hour (±6 hours) of ICU admission, both scores will be recalculated using cross-sectional measurements, allowing the calculation of Δ-SOFA2 and Δ-SOFA2-GIS (T72 - T24).
AGI grading will follow the original ESICM 2012 criteria, based on clinical symptoms, feeding intolerance, intra-abdominal pressure, gastric residual volume, diarrhea, and gastrointestinal bleeding. To ensure consistency across centers, all participating investigators will undergo standardized training on AGI assessment. Inter-rater agreement will be evaluated through a pilot phase using shared cases prior to the main enrollment period.
No additional interventions, laboratory tests, imaging studies, or sampling procedures will be performed for the purpose of this study. All data will be derived from information collected during routine clinical care.
Data Collection
Data will be collected at the participating sites using a standardized case report form. In addition to the SOFA2 and AGI components, the following variables will be recorded:
Demographic characteristics, comorbidities (Charlson Comorbidity Index), admission category, and admission diagnosis Vital signs, laboratory parameters, mechanical ventilation parameters (including plateau and peak airway pressures), vasopressor use, and renal replacement therapy requirement Sepsis status according to the Sepsis-3 definition Lactate values at baseline, 24th hour, and 72nd hour, and the 24-hour lactate clearance 24-hour cumulative fluid balance Daily caloric intake (DCI) averaged over the first 72 hours (kcal/kg/day) Feeding intolerance, gastrointestinal bleeding, intra-abdominal hypertension, abdominal compartment syndrome, and decompressive laparotomy Acute kidney injury staged according to KDIGO criteria Clinical outcomes: ICU and hospital length of stay, ventilator-free days, vasopressor-free days, renal replacement therapy-free days, 28-day mortality, and 90-day mortality Each participating site will record anonymized patient data into a shared spreadsheet template. The data will then be transferred to and consolidated at the coordinating center, which will not have access to patient identifiers.
Statistical Approach The discriminative performance of SOFA2 and SOFA2-GIS for predicting 28-day mortality (primary outcome) will be compared using the area under the receiver operating characteristic curve (AUC-ROC), with statistical comparison performed via the DeLong test. Calibration will be assessed using the Hosmer-Lemeshow test and calibration plots. Reclassification performance will be evaluated using the net reclassification improvement (NRI) and integrated discrimination improvement (IDI) indices. Multicollinearity between score components will be assessed using the variance inflation factor (VIF).
Secondary analyses will include: comparison of Δ-SOFA2 and Δ-SOFA2-GIS (T72 - T24) for outcome prediction, subgroup analyses by admission category (medical, surgical, septic) and AGI severity grade, evaluation of the interaction between lactate clearance and AGI grade, and the development of a clinically applicable nomogram based on the best-performing model.
Study Conduct The study will be conducted in accordance with the principles of the Declaration of Helsinki. The coordinating center is the Internal Medicine Intensive Care Unit of Ondokuz Mayıs University. Participating centers will join through an open call disseminated via Turkish intensive care societies, following completion of their respective institutional approvals. Each center will obtain its own local ethics committee approval prior to enrolling patients. Reporting will follow the TRIPOD+AI 2024 guideline.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 3 Months
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients (≥18 years) consecutively admitted to participating tertiary intensive care units in Türkiye. The study population includes both medical and surgical ICU admissions, with a broad mix of admission diagnoses representative of contemporary critical care practice. Patients will be enrolled regardless of underlying disease, as long as they meet eligibility criteria within the first 24 hours of ICU admission.
Key inclusion criteria (5 listed)
- Adults aged 18 years or older
- Admission to a participating intensive care unit
- Expected ICU length of stay of at least 24 hours
- Availability of clinical and laboratory data required to calculate the SOFA2 score and the AGI grade within the first 24 hours of ICU admission
- Written informed consent obtained from the patient or, when not feasible due to the patient's clinical condition, from a legally authorized representative
Key exclusion criteria (10 listed)
- Age younger than 18 years
- Pregnancy
- ICU length of stay shorter than 24 hours (including patients who die or are discharged within the first 24 hours)
- ICU readmission during the same hospital stay (only the index admission will be included)
- Postoperative admission for routine monitoring without organ dysfunction (planned short-term observation following elective surgery)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Comparison of discriminative performance between SOFA2 and SOFA2-GIS scores for 28-day all-cause mortality
Time frame: 28 days from ICU admission
The primary outcome is the difference in the area under the receiver operating characteristic curve (ΔAUC) between the SOFA2-GIS score and the SOFA2 score for predicting 28-day all-cause mortality. Both scores are calculated within the first 24 hours of ICU admission using the worst recorded values of each component. The Sequential Organ Failure Assessment 2 (SOFA2) score evaluates six organ systems (respiratory, cardiovascular, hepatic, renal, neurological, and coagulation), each scored from 0 to 4, with a total range of 0 to 24; higher scores indicate worse organ dysfunction. The SOFA2-GIS score combines SOFA2 with a gastrointestinal subscore (Grade 0-IV, scored 0-4) derived from the ESICM 2012 Acute Gastrointestinal Injury classification, with a total range of 0 to 28; higher scores indicate worse organ dysfunction. The area under the receiver operating characteristic curve (AUC-ROC) ranges from 0.5 (no discrimination) to 1.0 (perfect discrimination); higher values indicate better
5 secondary outcomes
Difference in discriminative performance (ΔAUC) between SOFA2-GIS and SOFA2 for prediction of 90-day all-cause mortality
Time frame: 90 days from ICU admission
Difference in discriminative performance (ΔAUC) between SOFA2-GIS and SOFA2 for prediction of ICU mortality
Time frame: Through ICU discharge, up to 60 days from ICU admission
Difference in discriminative performance (ΔAUC) between Δ-SOFA2-GIS and Δ-SOFA2 for prediction of 28-day all-cause mortality
Time frame: From ICU admission to 28 days
Net Reclassification Improvement (NRI) of SOFA2-GIS over SOFA2 for 28-day all-cause mortality
Time frame: 28 days from ICU admission
Intensive care unit length of stay
Time frame: Up to 60 days from ICU admission
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 May 2026.
- Individual participant dataSharing planned: Yes. De-identified individual participant data (IPD) collected during the SOFA2-GIS study, including all variables underlying the published findings, will be made available. The dataset will include patient demographics, comorbidities, admission diagnosis, SOFA2 and AGI score components, laboratory parameters, hemodynamic and ventilatory parameters, lactate values, daily caloric intake, fluid balance, complications, and clinical outcomes (28-day, ICU, hospital, and 90-day mortality, length of stay, ventilator-free days, vasopressor-free days, RRT-free days). All direct patient identifiers will be removed prior to data sharing.
Related trials for Critical Illness
Active, not recruiting
PICU Up!: A Pilot Stepped-wedge Trial of a Multicomponent Early Mobility Intervention for Critically Ill Children
Critical Illness
Not yet recruiting
Building Resilience Through Anxiety Virtual Education in PICU Survivors
Critical Illness Recovery, Mental Health
Active, not recruitingObservational study
Adverse Events During Physical Therapy in Neurocritical ICU Patients
Critical Illness, Brain Injury
Recruiting
Effectiveness of Virtual Reality in Improving Upper Limb Function in Critically Ill Patients
Intensive Care Unit (ICU) Acquired Weakness (ICU - AW), Critical Illness
RecruitingObservational study
Metabolic and Functional Study of γδ T Cells in Critically Ill Patients
Sepsis, Critical Illness
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Melda Isevi, MD contact
Ozkul Yilmaz Colak, MD study director
Ondokuz Mayıs University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Critical Illness and Multiple Organ Failure, run by Ozkul Yilmaz Colak at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 26 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ozkul Yılmaz Colak, MD (905063349266, ozkulyilmaz.colak@omu.edu.tr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Comparison of discriminative performance between SOFA2 and SOFA2-GIS scores for 28-day all-cause mortality (time frame: 28 days from ICU admission). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 May 2026; AzTrials last refreshed its copy on 31 Oct 2026.